Clinical Trials
3 trialsNCT05862194 2023-08-22
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Yuhan Corporation
Completed
NCT05716672 2023-02-08
Impact of Lazertinib Dose Modification on Effectiveness and Safety
Pusan National University Hospital
Unknown
NCT05377788 2022-05-19
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
Samsung Medical Center
Unknown